Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial

Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial

Abstract Background In the severe forms of COVID-19 and many other infectious diseases, the patients develop a cytokine storm syndrome (CSS) where pro-inflammatory cytokines such as IL-6 and TNF-α play a key role in the development of this serious process. Selenium and iron are two important trace m...

Full description

Bibliographic Details
Main Authors: Maryam Hafizi, Somayeh Kalanaky, Saideh Fakharzadeh, Pegah Karimi, Atefeh Fakharian, Somayeh Lookzadeh, Esmaeil Mortaz, Maryam Sadat Mirenayat, Jalal Heshmatnia, Mehrdad Bakhshayesh Karam, Homa Zamani, Alireza Nadji, Mihan Pourabdollah Toutkaboni, Saeed Oraee-Yazdani, Mohammad Esmaeil Akbari, Hamidreza Jamaati, Mohammad Hassan Nazaran
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Trials
Subjects:
COVID-19
BCc1
Hep-S
Nanochelating technology
IL-6
Cytokine storm syndrome
Online Access:https://doi.org/10.1186/s13063-023-07624-2

Similar Items

Similar Items